在同步进行的代谢功能障碍相关脂肪性肝病临床试验中，勃林格殷格翰公司宣布了其药物Survodutide的积极数据。结果显示，接受Survodutide治疗的患者中，有高达84.2%的人实现了肝脏脂肪含量减少至少30%的目标。这一疗效数据与安慰剂组形成了鲜明对比——后者仅有24.3%的患者达到相同标准。
该数据凸显了Survodutide在减少肝脏脂肪堆积方面的显著潜力，为治疗这一日益普遍的肝脏疾病带来了新的希望。随着非酒精性脂肪性肝病领域竞争加剧，包括
在同步进行的代谢功能障碍相关脂肪性肝病临床试验中，勃林格殷格翰公司宣布了其药物Survodutide的积极数据。结果显示，接受Survodutide治疗的患者中，有高达84.2%的人实现了肝脏脂肪含量减少至少30%的目标。这一疗效数据与安慰剂组形成了鲜明对比——后者仅有24.3%的患者达到相同标准。
该数据凸显了Survodutide在减少肝脏脂肪堆积方面的显著潜力，为治疗这一日益普遍的肝脏疾病带来了新的希望。随着非酒精性脂肪性肝病领域竞争加剧，包括
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.